Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 40 resultados

GRASSHOPPER: The GRASSHOPPER network Jumping forward from preclinical development of pediatric cancer drugs to c... Every year 16.000 children in Europe are diagnosed with cancer, and 2000 children (approximately 70 school classes) die from this illness. N...
2024-10-24 - 2028-11-30 | Financiado

MUTAPREDICT: Benchmarking AI to predict mutagenicity by combing chemical structure and genome wide mutation data PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV tramitó un HORIZON EUROPE: ERC-2024-POC Assessing mutagenicity, the capacity of a substance to cause permanent and potentially harmful changes to an organism's DNA, is a pivotal co...
2024-09-26 - 2026-03-31 | Financiado

SCARLET: Scaling up early and late effects research in Lithuanian childhood cancer survivors through educatio... PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV participó en un HORIZON EUROPE: HORIZON-WIDERA-2023-ACCESS-02 The SCARLET (SCAling up early and late effects Research in Lithuanian childhood cancer survivors through Education and Twinning) proposal ai...
2024-05-07 - 2027-09-30 | Financiado

Dypha: Dypha: adding the dimension of time to cell culture PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV participó en un HORIZON EUROPE: HORIZON-EIC-2023-TRANSITION-01 The current preclinical drug development pipeline is highly inefficient with 9 out of 10 drugs failing when first tested in humans. Of those...
2024-03-12 - 2027-03-31 | Financiado

FINDR: Spatiotemporal characterization of extrachromosomal DNA transcription and its key regulators in canc... PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Extrachromosomal circular DNA (ecDNA) present in cancer cells stochastically amplifies oncogenes and drug resistance genes independent from...
2024-03-11 - 2026-03-31 | Financiado

RESTART: How is blood (re-)made? Regeneration of human hematopoietic stem cells after transplantation PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV tramitó un HORIZON EUROPE: ERC-2023-STG How hematopoietic stem and progenitor cells (HSPCs) regenerate blood is a major unsolved question, frustrating their effective use for thera...
2023-10-12 - 2028-12-31 | Financiado

GlycoMap: Integrated Glycomics for Cancer Precision Medicine PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV participó en un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Breast Cancer is the most commonly diagnosed cancer in Europe and remains the first cause of cancer death in women (nearly 92,000 deaths in...
2023-04-11 - 2025-08-31 | Financiado

Maxima Butterfly: From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-COFUND-01 Every year, around 600 children in the Netherlands get cancer and one in four children dies from this illness. More than ten years ago, a gr...
2023-01-01 - 2027-12-31 | Financiado

MELCAYA: Novel health care strategies for melanoma in children adolescents and young adults PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV participó en un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 "In childhood, adolescence and young adults (CAYA), melanoma is under-studied and non-existing tailored clinical guidelines and standardized...
2022-12-01 - 2026-11-30 | Financiado

Maxima Butterfly: From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-COFUND-01 Every year, around 600 children in the Netherlands get cancer and one in four children dies from this illness. More than ten years ago, a gr...
2022-10-10 - 2027-12-31 | Financiado

PanCareSurPass: PanCare studies of the scale up and implementation of the digital Survivorship Passport to improve p... PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV participó en un H2020: H2020-SC1-BHC-2018-2020 Almost 500,000 former childhood cancer patients (CCS) are now living in Europe. Compared to the general population, CCS represent a vulnerab...
2021-01-21 - 2025-02-28 | Financiado

diaRNAgnosis: A novel platform for the direct profiling of circulating cell free ribonucleic acids in biofluids PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV participó en un H2020: H2020-MSCA-RISE-2020 Circulating cell-free ribonucleic acids (ccfRNAs) represent an emerging and important class of molecules, able to provide significant clinic...
2020-10-02 - 2025-05-31 | Financiado

VAGABOND: Validation of Actionable Genomic ABerrations in a paediatric Oncology Network for Doctorate students PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV tramitó un H2020: H2020-MSCA-ITN-2020 Pre-clinical drug development for paediatric cancers is very complex, resource intensive and requiring multi-disciplinary expertise and inno...
2020-08-18 - 2024-11-30 | Financiado

TREL: Twinning in Research and Education to improve survival in Childhood Solid Tumours in Lithuania PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV participó en un H2020: H2020-WIDESPREAD-2018-2020 Vilnius University Hospital Santaros Klinikos (VULSK) acts as a coordinator of the TREL (Twinning in Research and Education to improve survi...
2020-06-12 - 2023-12-31 | Financiado

SecondCANCERinKIDS: What causes therapy related malignancies in childhood cancer survivors? Dissecting the etiology of s... PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV tramitó un H2020: ERC-2019-COG Therapy-related malignancies are a major cause of long-term mortality among childhood cancer survivors. However, it is unclear how exposure...
2020-03-19 - 2025-03-31 | Financiado

PrinsesMaximaCentrumvoorKinderoncologie